Chronic Spontaneous Urticaria

World Urticaria Day raises awareness about chronic spontaneous and inducible urticaria, highlighting treatment advancements and patient challenges.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Based on the diagnosis and treatment challenges of CSU, it’s crucial for allergists and dermatologists to work together toward an effective approach based on the latest evidence.

Patients switched from placebo to remibrutinib at week 24 showed similar reductions in autoantibodies by week 52.

According to a poster at the 2025 EADV Congress, barzolvolimab achieved comparable improvements in weekly Urticaria Activity Scores across immunoglobulin E (lgE) subgroups.

This review of the latest dermatologic studies highlights new research on novel image fusion for tongue SCC, persistent nodules following HA fillers, rice bran extract for wound healing, and more.

Explore the potential of dupilumab for treating omalizumab-resistant chronic spontaneous urticaria, offering new hope for affected patients.

Explore how model-informed drug development shapes ligelizumab's journey in treating chronic spontaneous urticaria, despite its eventual discontinuation.

Explore the latest strategies for managing CSU, including personalized therapies and updated 2025 guidelines for effective treatment.

EAACI's report highlights current practices and challenges in diagnosing and managing chronic urticaria in pediatric patients, emphasizing the need for improved education and resources.

Explore effective strategies for managing CSU, including tailored therapies and the latest treatment advancements for optimal patient care.

This review of the latest dermatologic studies focuses on chronic spontaneous urticaria with new research on the transition from omalizumab to dupilumab, metabolic syndrome in urticaria patients, current pediatric CSU guidelines, and more.

The randomized, placebo-controlled trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 150 healthy volunteers.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore how synthetic data revolutionizes CSU research, enabling smaller sample sizes and enhancing trial efficiency and inclusivity.

According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.

New findings at Elevate Derm highlight remibrutinib's rapid and sustained efficacy in reducing chronic spontaneous urticaria symptoms, offering hope for patients.

Explore how genetic factors influence acute and chronic urticaria, revealing potential for personalized treatment strategies.

Jasper Therapeutics reveals promising results from briquilimab trials for chronic spontaneous urticaria, showcasing strong efficacy and safety despite manufacturing challenges.

Researchers found CU was associated with increased odds of developing anxiety, depression, PTSD, and substance use disorder, among other conditions.

Treatment with rupatadine led to improvements in CSU and chronic inducible urticaria.

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine-refractory CSU.

Research reveals a significant link between TNF-alpha serum levels and the severity of chronic spontaneous urticaria, suggesting new therapeutic avenues for treatment.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.